Source comparison
CJC-1295 No DAC Recovery Results Timeline: Comparison by Protocol Type
Injury Recovery Research 200mcg 3x/week (Mon/Wed/Fri) 6–8 hours post-dose, sustained 6–10 days Reduced inflammation markers (CRP, IL-6) by day 7–10; improved tissue healing scores (ultrasound elastography) by day 14–21 4–8 weeks Best application for CJC-1295 n
This comparison does not assign a generated winner or score.
- Injury Recovery Research
- 200mcg 3x/week (Mon/Wed/Fri)
- 6–8 hours post-dose, sustained 6–10 days
- Reduced inflammation markers (CRP, IL-6) by day 7–10; improved tissue healing scores (ultrasound elastography) by day 14–21
- 4–8 weeks
- Best application for CJC-1295 no DAC. Targets the exact mechanism (IGF-1-mediated tissue repair) the peptide optimises
- Athletic Performance Enhancement
- 100mcg 2x/week (pre-bed on heavy training days)
- 6–8 hours post-dose
- Reduced DOMS duration (48h → 24–36h) by day 10; strength improvement 3–5% by day 21
- 8–12 weeks
- Effective when paired with periodised training; marginal benefit without structured load progression
- General Recovery Optimization
- 100mcg 1x/week (maintenance dosing)
- Subjective sleep quality improvement by day 5–7; minimal measurable body composition change
- 12+ weeks
- Suboptimal dosing frequency for most study outcomes. Weekly dosing maintains baseline IGF-1 elevation but insufficient for tissue adaptation
- Body Recomposition Research
- 150mcg 3x/week + caloric deficit or surplus
- Lean mass preservation in deficit (0.5kg over 8 weeks); lean mass gain in surplus (0.8–1.2kg over 8 weeks)
- 8–16 weeks
- Requires precise macronutrient tracking; peptide effect is conditional on energy availability and protein intake